LOXITANE C Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Loxitane C, and what generic alternatives are available?
Loxitane C is a drug marketed by Teva Branded Pharm and is included in one NDA.
The generic ingredient in LOXITANE C is loxapine hydrochloride. There are eight drug master file entries for this compound. Additional details are available on the loxapine hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LOXITANE C?
- What are the global sales for LOXITANE C?
- What is Average Wholesale Price for LOXITANE C?
Summary for LOXITANE C
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 13 |
| Clinical Trials: | 1 |
| Patent Applications: | 382 |
| DailyMed Link: | LOXITANE C at DailyMed |
Recent Clinical Trials for LOXITANE C
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Mylan Pharmaceuticals | Phase 1 |
US Patents and Regulatory Information for LOXITANE C
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Branded Pharm | LOXITANE C | loxapine hydrochloride | CONCENTRATE;ORAL | 017658-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LOXITANE C
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Teva Branded Pharm | LOXITANE C | loxapine hydrochloride | CONCENTRATE;ORAL | 017658-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Teva Branded Pharm | LOXITANE C | loxapine hydrochloride | CONCENTRATE;ORAL | 017658-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for LOXITANE C
See the table below for patents covering LOXITANE C around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Switzerland | 517759 | Verfahren zur Herstellung 11-basisch substituierter Dibenz(b,f)-1,4-oxazepine und Dibenzo(b,e)-1,4-diazepine | ⤷ Sign Up |
| Netherlands | 6803570 | ⤷ Sign Up | |
| France | 1386724 | 5-nitro-2-furylthioamide | ⤷ Sign Up |
| Switzerland | 484924 | Verfahren zur Herstellung basisch substituierter Heterocyclen | ⤷ Sign Up |
| Sweden | 364277 | ⤷ Sign Up | |
| Germany | 1720007 | ⤷ Sign Up | |
| Belgium | 712114 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for LOXITANE C
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1389098 | C300609 | Netherlands | ⤷ Sign Up | PRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220 |
| 1389098 | SPC/GB13/055 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: LOXAPINE; REGISTERED: UK EU/1/13/823/001 20130220; UK EU/1/13/823/002 20130220 |
| 1389098 | 2013C/054 | Belgium | ⤷ Sign Up | PRODUCT NAME: LOXAPINE; AUTHORISATION NUMBER AND DATE: EU/1/13/823/001 20130225 |
| 1389098 | 300609 | Netherlands | ⤷ Sign Up | PRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
